ASMB - Assembly Biosciences

-

$undefined

N/A

(N/A)

Assembly Biosciences NASDAQ:ASMB Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio's approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio's strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.

Location: | Website: www.assemblybio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-5.627M

Cash

109.2M

Avg Qtr Burn

N/A

Short % of Float

0.46%

Insider Ownership

31.62%

Institutional Own.

18.57%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ABI-5366 Details
Genital herpes (HSV), Sexually transmitted infections
No event data in pipeline
ABI-4334 Details
Liver infection, Hepatitis B, Liver disease

Phase 1b

Data readout

Vebicorvir (VBR, ABI-H0731) Details
Liver infection, Chronic liver disease, Hepatitis B

Failed

Discontinued

ABI-H2158 Details
Liver infection, Liver disease, Hepatitis B

Failed

Discontinued

ABI-H3733 Details
Liver disease, Hepatitis B, Liver infection

Failed

Discontinued